Mirena IUD lawsuit: how the substantially-closed MDLs 2434 and 2767 framework actually worked and the emerging breast cancer claims

The Bayer Mirena intrauterine device (IUD) litigation operated through two distinct multidistrict litigation proceedings that together address the substantial product liability framework for substantial Mirena IUD complications. Both MDLs are now substantially closed with substantial substantive limitations on substantial subsequent claims. MDL 2434 (In re: Mirena IUD Products Liability Litigation), pending in the U.S. District Court for the Southern District of New York, addressed substantial perforation and migration claims and substantially resolved through substantial individual settlements and substantial substantive dismissals over 2014-2018. MDL 2767 (In re: Mirena IUS Levonorgestrel-Related Products Liability Litigation), established April 2017 in the U.S. District Court for the Southern District of New York before Judge Paul Engelmayer, addressed substantial pseudotumor cerebri (PTC) and idiopathic intracranial hypertension (IIH) claims and substantially closed December 8, 2020 after substantial Daubert determinations excluded plaintiff expert witnesses on substantial causation.

The substantive theory in MDL 2767 centered on the substantial allegation that the synthetic hormone levonorgestrel released by Mirena substantially caused substantial abnormal elevation of cerebrospinal fluid in the skull resulting in substantial pseudotumor cerebri (substantially called idiopathic intracranial hypertension when no underlying cause is identified). The substantial substantive condition substantially produces substantial elevated intracranial pressure substantially without an underlying tumor — substantially mimicking substantial brain tumor symptoms including substantial severe migraine-type headaches, substantial vision changes, substantial papilledema (optic nerve swelling), substantial tinnitus (ringing in ears), substantial diplopia (double vision), and in substantial severe cases substantial permanent vision loss. The substantial substantive framework substantially relied on substantial scientific evidence connecting substantial levonorgestrel exposure to substantial PTC/IIH development. The substantial substantive failure occurred when Judge Engelmayer substantially excluded plaintiff expert witnesses through substantial Daubert determinations — substantially ruling that substantial proposed expert testimony substantially did not reliably establish substantial scientific causation between substantial Mirena's levonorgestrel hormone and substantial IIH/PTC.

The substantial emerging Mirena breast cancer claims represent substantial subsequent litigation framework. Substantial recent medical literature substantially indicates substantial potential association between substantial levonorgestrel-releasing IUDs and substantial breast cancer risk. Substantial new lawsuits substantially building momentum in 2026 substantially allege that Bayer substantially failed to adequately warn women about substantial breast cancer risks from Mirena and substantial similar levonorgestrel-releasing products. Multiple law firms substantially accept new Mirena breast cancer cases in 2026 with substantial bellwether trials substantially expected mid-to-late 2026. No global settlement has substantially been reached as of substantial publication. Substantial first bellwether trial outcomes will substantially shape settlement negotiations for substantial subsequent cases. The substantial emerging litigation framework substantially provides substantial subsequent procedural opportunity for substantial Mirena users with substantial breast cancer diagnoses.

This is how the Mirena IUD litigation actually worked through MDL 2434 (substantially closed) and MDL 2767 (closed December 2020), the substantive theories of substantial perforation/migration and substantial PTC/IIH claims, the substantial Daubert framework that closed MDL 2767, the substantial emerging breast cancer claim framework, and the strategic considerations for substantial Mirena users.

What Mirena is and the alleged complications

Mirena (manufactured by Bayer):

Hormonal intrauterine device (IUD)
Releases levonorgestrel (synthetic progestin)
Released into uterus over substantial 5-7 year period
FDA-approved (remains commercially available)
Substantial substantive contraceptive product

Substantial alleged complications:

Perforation and migration (MDL 2434 framework)

Substantial substantive framework:

Uterine perforation. Substantial:

Device punctures uterine wall
Substantial substantive complications
Substantial subsequent surgery required
Substantial individual analysis

Device migration. Substantial:

Device moves from intended position
May migrate into abdomen
Substantial complications
Substantial surgical intervention required

Substantial substantive complications:

Infertility
Substantial scarring
Bowel perforation
Bladder perforation
Substantial substantive complications

Pseudotumor cerebri / IIH (MDL 2767 framework)

Substantial substantive framework:

Substantial substantive condition:

Elevated intracranial pressure
Without underlying tumor
Substantial substantive condition
"Pseudotumor cerebri" (false brain tumor)
"Idiopathic intracranial hypertension" (when cause unknown)

Substantial alleged mechanism:

Levonorgestrel hormone
Substantial elevation of cerebrospinal fluid
Substantial substantive theory
Substantial substantive failure on Daubert review

Substantial symptoms:

Severe migraine-type headaches
Vision changes (blurred, double vision)
Vision loss (sometimes permanent)
Papilledema (optic nerve swelling)
Tinnitus (ringing in ears)
Substantial substantive complications

Substantial substantive treatment:

Substantial medication
Substantial procedural shunt placement (severe cases)
Substantial monitoring
Substantial substantive intervention

Emerging breast cancer claims (2026 framework)

Substantial substantive emerging framework:

Substantial substantive theory:

Levonorgestrel exposure
Substantial breast cancer risk increase
Substantial substantive failure to warn
Substantial substantive product liability framework

Substantial substantive evidence:

Substantial medical literature
Substantial epidemiological data
Substantial substantive emerging framework

Substantial substantive claims:

Failure to warn
Substantial product liability
Substantial substantive theory
Substantial individual analysis

The procedural history of MDL 2434 (perforation/migration)

Procedural timeline

2013. MDL 2434 established in S.D.N.Y.:

Substantial substantive framework
Substantial procedural framework
Substantial perforation/migration claims

2014-2018. Substantial discovery and motion practice. Substantial individual case development.

Substantial substantive Daubert framework. Substantial:

Substantial substantive scientific evidence framework
Substantial substantive failure for some categories
Substantial individual case framework

2014-2018. Many cases substantially settled. Substantial confidential framework.

Substantial substantive completion. Substantial:

Substantial individual settlements
Substantial procedural framework
Substantial substantive resolution

The procedural history of MDL 2767 (PTC/IIH)

Procedural timeline

2016. Substantial individual lawsuits filed alleging PTC/IIH from Mirena.

April 2017. Judicial Panel on Multidistrict Litigation establishes MDL 2767 in S.D.N.Y. Judge Paul Engelmayer assigned.

2017-2019. Substantial discovery and motion practice. Substantial substantive scientific evidence development.

April 2018. Substantial Daubert hearings on substantial expert witness causation testimony.

Substantial 2019. Judge Engelmayer substantially excludes plaintiff expert witnesses:

Substantial Daubert determinations
Substantial substantive ruling on causation
Substantial substantive analysis
Substantial procedural framework

Substantial substantive procedural framework:

Substantial expert testimony excluded
Substantial subsequent procedural framework
Substantial substantive impact

December 8, 2020. MDL 2767 substantially closes:

Substantial substantive completion
Substantial procedural framework
Substantial substantive impact

Substantial appeals. Substantial:

Substantial individual appeals
Substantial substantive framework
Substantial procedural framework

Emerging breast cancer claims framework (2026)

Substantial substantive emerging framework

Substantial substantive framework:

Substantial new claims building 2026. Substantial:

Substantial procedural framework
Substantial substantive theory
Substantial individual analysis

Substantial bellwether trials expected. Substantial:

Mid-to-late 2026 framework
Substantial procedural framework
Substantial substantive outcomes will shape settlement

Substantial substantive theory:

Levonorgestrel-breast cancer association
Substantial medical literature support
Substantial substantive failure to warn
Substantial substantive product liability

Substantial procedural status:

No global settlement reached
Substantial individual case framework
Substantial procedural framework
Substantial substantive emerging framework

Substantial substantive emerging legal framework

Substantial substantive framework:

Substantial recent regulatory framework:

FDA labeling
Substantial substantive monitoring
Substantial substantive analysis
Substantial individual analysis

Substantial substantive law firm activity:

Multiple firms accepting cases 2026
Substantial substantive procedural framework
Substantial individual analysis

Eligibility framework

For prospective Mirena breast cancer plaintiffs:

Documenting Mirena use

Critical first step. Identify Mirena use specifically:

Medical records
Provider records identifying specific IUD
Manufacturer identification (Bayer specifically)
Insertion date and removal date
Duration of use
Substantial product-specific identification

Important note. Many IUD manufacturers:

Bayer Mirena (this litigation)
Bayer Skyla (similar levonorgestrel device)
Bayer Liletta (similar levonorgestrel device)
Bayer Kyleena (similar levonorgestrel device)
ParaGard copper IUD (separate litigation, copper-based not hormonal)

The specific product determines which litigation framework applies.

Documenting the breast cancer diagnosis

Strong case requirements:

Diagnosis documentation:

Pathology reports
Hormone receptor status (ER, PR, HER2)
Substantial cancer staging
Substantial substantive diagnosis documentation
Substantial medical records

Treatment records:

Surgical pathology
Chemotherapy records
Radiation records
Hormonal therapy records
Substantial substantive treatment documentation

Substantial connection to Mirena:

Substantial temporal relationship (Mirena use preceding cancer diagnosis)
Substantial medical evaluation supporting causation
Substantial expert witness preparation
Substantial documentation of connection

Statute of limitations analysis

Most states have 2-4 year limitations from injury or discovery:

Discovery rule may apply
Substantial individual variation
Specific state law analysis required
Substantial counsel evaluation needed

Substantial substantive framework for Mirena PTC/IIH cases:

MDL 2767 substantially closed
Substantial procedural difficulty for substantial subsequent cases
Substantial professional analysis valuable

Substantial substantive framework for Mirena breast cancer cases:

Emerging litigation
Substantial procedural opportunity
Substantial individual analysis

How Mirena litigation compares to other women's health mass torts

The framework has distinctive features:

Compared to ParaGard IUD MDL 2974: Both IUD litigation. ParaGard substantial active framework with substantial bellwether trials. Mirena substantially closed framework with emerging breast cancer claims.

Compared to Depo-Provera litigation: Both contraceptive hormone litigation. Depo-Provera substantial meningioma framework. Mirena PTC/IIH framework substantially failed Daubert; substantial breast cancer claims emerging.

Compared to Hair relaxer cancer MDL 3060: Both involve cancer claims related to consumer products. Hair relaxer substantial active framework. Mirena breast cancer substantial emerging framework.

Compared to NEC infant formula litigation: Both involve substantial product safety claims affecting women/infants. Different therapeutic areas.

Compared to Bard hernia mesh MDL 2846: Both involve substantial active and closed phases. Different product categories.

Distinctive Mirena features:

Two substantially closed MDLs (2434 and 2767)
MDL 2767 closed December 8, 2020
Substantial Daubert framework failure for PTC/IIH
Judge Paul Engelmayer expert exclusions
Substantial Bayer defendant
Substantial levonorgestrel hormone product
Emerging breast cancer claims (2026 framework)
Substantial multi-injury allegation framework
Substantial FDA-approved status (still commercially available)
Substantial substantive scientific causation challenges (PTC/IIH)
Substantial substantive emerging causation framework (breast cancer)
Substantial substantive procedural framework

Settlement projections

Settlement valuation varies substantially:

Substantial substantive framework for Mirena PTC/IIH cases:

Substantially closed framework
Substantial procedural limitation
Substantial substantive difficulty

Substantial substantive framework for Mirena perforation/migration cases:

Most substantially settled 2014-2018
Substantial confidential settlements
Substantial individual analysis

Substantial substantive framework for emerging Mirena breast cancer cases:

Substantial bellwether trials expected mid-to-late 2026
No global settlement yet
Substantial individual analysis
Substantial professional involvement valuable

Substantial substantive emerging breast cancer settlement projections:

Pending bellwether outcomes
Substantial individual case analysis
Substantial substantive complexity
Substantial professional involvement valuable

Tax implications. Personal injury settlements for physical injuries are tax-free under IRC §104(a)(2). Coordinate with tax counsel for substantial settlements, particularly when other tax debt issues or §72(t) early withdrawal considerations exist.

Strategic considerations

For affected Mirena users:

Identify Mirena use specifically. Critical first step:

Medical records
Provider identification
Manufacturer verification (Bayer specifically)
Product identification (Mirena specifically — not Skyla, Liletta, or Kyleena)
Insertion and removal dates
Duration of use
Substantial documentation requirement

Address the substantial closed MDL framework. Substantial:

MDL 2434 substantially closed
MDL 2767 closed December 8, 2020
Substantial procedural framework
Substantial individual analysis required

Engage experienced women's health mass tort counsel. Substantial:

Mirena-specific experience valuable
Substantial procedural framework
Statute of limitations defenses
Substantial firm-specific Bayer experience valuable

Address emerging Mirena breast cancer claims if applicable. Substantial:

Substantial new framework building 2026
Bellwether trials expected mid-to-late 2026
Substantial substantive theory
Substantial professional involvement valuable

Document substantial breast cancer diagnosis if applicable:

Pathology reports
Hormone receptor status
Substantial cancer staging
Treatment records
Substantial substantive documentation

Document Mirena use timing:

Insertion date
Removal date
Duration of use
Substantial temporal relationship to cancer diagnosis
Substantial individual analysis

Address substantial federal preemption considerations. Substantial:

FDA approval status
Substantial substantive defense by manufacturers
Substantial procedural framework
Substantial professional analysis

Plan for the substantial Daubert framework for PTC/IIH cases. Substantial:

Judge Engelmayer ruling substantially excluded experts
Substantial substantive challenge for PTC/IIH cases
Substantial procedural framework
Substantial individual analysis

Address state court alternatives. Substantial:

Some Mirena cases substantially proceed in state court
Substantial procedural framework
Substantial state-specific law
Substantial counsel coordination

Document subsequent medical treatment. Strong cases include:

All medical care related to Mirena complications
Substantial treatment documentation
Substantial procedural framework

Coordinate with treating physicians. Substantial:

OB/GYNs, primary care
Oncologists for cancer cases
Substantial expert witness preparation
Substantial substantive framework

Plan for the substantial growth loss when accessing retirement funds. Some plaintiffs:

Need retirement funds for medical expenses
§72(t) early withdrawal substantial cost
Substantial coordination required
May benefit from medical expense exception

Address related tax planning. Personal injury settlements for physical injuries are tax-free. Coordinate with tax counsel for substantial settlements. Component allocation (physical injury vs. emotional distress) affects tax treatment.

Watch the wrongful death framework. Some severe cases:

Substantial complications causing death
Substantial breast cancer cases causing death
Substantial state law variation
Estate has standing
Surviving family members may have separate claims

Document the lifestyle impact. Strong cases show:

Pre-Mirena baseline
Loss of function post-Mirena
Inability to return to work
Daily life impact

Plan for extended timeline. Substantial:

Substantial procedural framework
Substantial individual case analysis
Substantial wait for resolution

Address the multiple IUD manufacturer landscape carefully. Many products:

Bayer Mirena (this litigation)
Bayer Skyla, Liletta, Kyleena (similar levonorgestrel products)
ParaGard copper IUD (separate litigation)
Various other manufacturer products

Identify specific product; substantially different procedural framework for each.

Watch for the emerging breast cancer framework momentum. Substantial:

Substantial new cases building 2026
Substantial bellwether trials mid-to-late 2026
Substantial procedural framework
Substantial professional involvement valuable

Coordinate with LLC asset protection if substantial business assets at risk. Substantial settlements may affect:

Business asset planning
Estate planning
Substantial coordination required

Plan for substantial Bayer corporate framework. Substantial:

Substantial corporate financial capacity
Substantial substantive framework
Substantial procedural framework

Address the time-sensitive nature. Substantial:

Statute of limitations running
Substantial individual deadlines
Substantial counsel evaluation needed
Substantial procedural framework

Watch substantial Bayer-related litigation. Substantial:

Roundup (substantial separate litigation)
Various other Bayer products
Substantial coordination considerations
Substantial individual analysis

Document substantial pathology results carefully. Substantial:

Substantial substantive evidence
Substantial expert witness preparation
Substantial procedural framework

Plan substantial expert witness preparation:

Substantial substantive framework
Substantial Daubert preparation
Substantial individual analysis
Substantial professional involvement valuable

Address substantial federal preemption challenges:

FDA approval defense
Substantial procedural framework
Substantial substantive analysis
Substantial individual analysis

Plan substantial bellwether monitoring (breast cancer):

Substantial mid-to-late 2026 framework
Substantial procedural framework
Substantial individual analysis
Substantial professional involvement valuable

Document substantial medical literature supporting causation:

Substantial epidemiological evidence
Substantial substantive support
Substantial procedural framework
Substantial substantive analysis

Watch substantial regulatory framework:

FDA labeling updates
Substantial substantive monitoring
Substantial procedural framework
Substantial individual analysis

Address substantial multi-year monitoring:

Substantial bellwether outcomes
Substantial settlement framework development
Substantial substantive evolution
Substantial individual analysis

Plan substantial state law variations:

Substantial state-specific law
Substantial procedural framework
Substantial individual analysis
Substantial professional involvement valuable

Engage qualified counsel. Substantial:

Women's health mass tort attorneys
Mirena-specific experience valuable
Substantial professional benefit
Substantial procedural framework

For affected Mirena users, the substantial litigation framework reflects substantial historical and substantial emerging procedural realities. The substantially closed MDL 2434 framework that addressed substantial perforation and migration claims through substantial individual settlements over 2014-2018 substantially provides substantial limited procedural opportunity for substantial subsequent perforation/migration cases given substantial closed MDL framework and substantial statute of limitations considerations. The substantially closed MDL 2767 framework that addressed substantial pseudotumor cerebri (PTC) and idiopathic intracranial hypertension (IIH) claims substantially closed December 8, 2020 after substantial Judge Paul Engelmayer Daubert determinations substantially excluded substantial plaintiff expert witnesses on substantial causation between substantial levonorgestrel hormone and substantial IIH/PTC — substantially substantial substantive framework that substantially complicates substantial subsequent PTC/IIH cases given the substantial Daubert precedent. The substantial emerging Mirena breast cancer claim framework substantially represents substantial subsequent procedural opportunity for substantial Mirena users with substantial breast cancer diagnoses, with substantial bellwether trials substantially expected mid-to-late 2026 and substantial substantive theory substantially alleging that Bayer substantially failed to adequately warn women about substantial breast cancer risks from substantial levonorgestrel-releasing IUDs. The work for affected Mirena users is in identifying substantial specific Mirena use through substantial medical records (distinguishing from substantial similar Bayer products including Skyla, Liletta, and Kyleena, and from substantial alternative IUD products including ParaGard copper IUD covered by substantial separate litigation framework), documenting substantial breast cancer diagnoses comprehensively through substantial pathology reports and substantial hormone receptor status, addressing substantial federal preemption challenges through substantial professional analysis given the substantial FDA approval status of Mirena, engaging experienced women's health mass tort counsel familiar with both substantial closed Mirena MDL frameworks and substantial emerging breast cancer litigation framework, monitoring substantial bellwether trial outcomes substantially expected mid-to-late 2026 to substantially understand substantial settlement framework development, and engaging in substantial subsequent procedural framework as substantial bellwether outcomes substantially shape substantial settlement negotiations and substantial substantive framework for substantial future cases against substantial Bayer for substantial alleged Mirena-related breast cancer claims.